drugset / Trial / NCT01743950
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Phase 2
Terminated
49 enrolled
University of Wisconsin, Madison
Genentech, Inc. · collabNational Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high grade gliomas (grade III and grade IV). Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior exposure to bevacizumab.
Timeline
- Start
- 2012-12-03
- Primary completion
- 2024-12-24
- Completion
- 2024-12-24
Outcome
Outcome not reported
Stopped (Enrollment): “slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |